A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Trial Profile

A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs SAR 260301 (Primary) ; Vemurafenib
  • Indications Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results for the dose-escalation phase in 21 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 09 Apr 2015 Status changed from recruiting to completed, according to ClincalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top